798P - Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advance...

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Urothelial Cancers
Presenter Aristotelis Bamias
Citation Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373
Authors A. Bamias1, K. Tzannis1, M. Liontos2, L. Harshman3, S.J. Crabb4, Y. Wong5, S.K. Pal6, T.B. Powles7, J. Bellmunt8, U. De Giorgi9, S. Ladoire10, N. Agarwal11, E.Y. Yu12, G. Niegisch13, C.N. Sternberg14, A. Alva15, S. Srinivas16, J. Rosenberg17, R. Investigators18
  • 1Clinical Therapeutics, National and Kapodistrian University of Athens, 115 28 - Athens/GR
  • 2Oncology Unit, Department Of Clinical Therapeutics, Alexandra Hospital, 115 28 - Athens/GR
  • 3Medical Oncology, Dana-Farber Cancer Institute, Boston/US
  • 4Medical Oncology, University of Southampton, Southampton/GB
  • 5Medical Oncology, Fox Chase Cancer Center, Philadelphia/US
  • 6Medical Oncology And Experimental Therapuetics, City of Hope, 91010 - Duarte/US
  • 7Department Of Medical Oncology, St. Bartholomew's Hospital, EC1A 7BE - London/GB
  • 8Oncology, Dana-Farber Cancer Institute, Boston, MA/US
  • 9Medical Oncology, Istituto Tumori della Romagna I.R.S.T., Meldola/IT
  • 10Medical Oncology, Centre Georges-François Leclerc (Dijon), Dijon/FR
  • 11Medical Oncology, Huntsman Cancer Institute, Salt Lake City/US
  • 12Medical Oncology, Univ. Washington/VAPSHCS, Seattle/US
  • 13Medical Oncology, Univesitätsklinikum Düsseldorf, Düsseldorf/DE
  • 14Medical Oncology, Azienda Ospedaliera S. Camillo Forlanini, Roma/IT
  • 15Medical Oncology, University of Michigan, East Lansing/US
  • 16Medical Oncology, Stanford University, Palo Alto/US
  • 17Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 18Oncology, Mount SInai Medical College, New York/US



Cisplatin-based chemotherapy is the treatment of choice in mUC. A significant proportion of patients do not receive chemotherapy, while about 50% of treated patients do not receive cisplatin. We used the multinational RISC database to map patterns of chemotherapy utilization and adherence to recently published UFC criteria (Galsky, 2011) in unselected mUC patients


Selection criteria: diagnosis of mUC, transitional-cell, mixed, squamous and adeno histologies.


Of 1974 mUC patients 475 (25%) did not receive 1st-line chemotherapy. No chemotherapy administration was associated with: non-pure TCC histology, higher Charslon Comorbidity Index (CCI), non-caucasian race, non-european country, low volume center (contribution of


Patterns of practice are influenced by various factors, such as age, co-morbidities, race, country of origin and volume of mUC patients. 25% of non-cisplatin treated patients were fit-for-cisplatin. Age and co-morbidities represent major factors, which lead to deviation from the established UFC criteria.

Clinical trial identification

Legal entity responsible for the study



Icahn School of Medicine, Mount Sinai USA


All authors have declared no conflicts of interest.